NCT07082439
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07082439
Title Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Abramson Cancer Center at Penn Medicine
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Abramson Cancer Center at the University of Pennsylvania RECRUITING Philadelphia Pennsylvania 19104 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field